Dr. Ellis on Measuring Endocrine Therapy Efficacy With Ki67

Dr. Ellis Discusses Ki67 as a Treatment Monitoring BiomarkerПодробнее

Dr. Ellis Discusses the Cell-Proliferation Marker Ki67Подробнее

Dr. Matthew Ellis on Heterogeneity Impacting Biomarker EfficacyПодробнее

Dr. Ellis Describes Breast Cancer HeterogeneityПодробнее

Dr. Ellis on Resistance to Endocrine Therapy in HR+ Metastatic Breast CancerПодробнее

Dr. Matthew Ellis on hormonal therapy before breast cancer surgeryПодробнее

Dr. Ellis on Neoadjuvant Endocrine Therapy for Breast CancerПодробнее

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes...Подробнее

Dr. Ellis Considers the Use of Biosimilars in OncologyПодробнее

The use of the Ki-67 in deciding which patients with HR+ breast cancer can safely avoid chemotherapyПодробнее

Dr. Ellis on Adjuvant CDK4/6 Inhibition in HR-Positive Breast CancerПодробнее

LUMINA results: Women with low levels of the Ki67 biomarker can avoid outcomes related to RTПодробнее

Priya Rastogi, MD, provides details on the subgroup of patients with Ki-67 status from monarchEПодробнее

Dr. Verma on HER2 Testing and the Utility of Ki67Подробнее

Ki-67 index after neoadjuvant ET as a prognostic biomarker for HR+/HER2- early breast cancerПодробнее

Dr. Ellis Discusses the Future of the PI3-Kinase PathwayПодробнее

How to use endocrine therapy in premenopausal women with ER+ early breast cancerПодробнее

Dr. Ellis on Potential Impact of CDK4/6 Inhibitors in Breast CancerПодробнее

PerELISA: de-escalated therapy for HR+/HER2+ BC with Ki67 response following 2-week letrozoleПодробнее